摘要
目的探讨布地奈德福莫特罗联合孟鲁司特钠治疗支气管哮喘的疗效及对炎症因子水平的影响。方法回顾性分析2016年7月至2018年7月在北京市大兴区人民医院住院的60例支气管哮喘患者的临床资料,按照治疗方法不同分为观察组和对照组,各30例。其中,对照组给予布地奈德福莫特罗治疗,观察组在对照组的基础上联合孟鲁司特钠治疗,1周为1个疗程,均治疗4个疗程。比较两组患者治疗后的临床疗效,治疗前后的肺功能指标[第一秒用力呼气量(FEV1)、呼气流量峰值(PEF)、用力肺活量(FVC)]、炎症因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平以及不良反应发生率。结果观察组总有效率高于对照组[93. 33%(28/30)比73. 33%(22/30)](P <0. 05)。治疗后,两组患者的FEV1、PEF、FVC均升高,且观察组高于对照组[(82. 90±6. 71)%比(78. 40±6. 82)%,(3. 96±0. 48) L/s比(3. 59±0. 41) L/s,(3. 39±0. 37) L比(3. 09±0. 33) L](P <0. 05)。治疗后,两组患者的血清CRP、IL-6、TNF-α水平均降低,且观察组低于对照组[(164. 8±11. 6) ng/L比(187. 1±21. 8) ng/L,(4. 3±1. 1) ng/L比(7. 3±1. 7) ng/L,(131. 5±15. 2)μg/L比(149. 8±17. 2)μg/L](P <0. 05)。观察组总不良反应发生率为16. 67%(5/30),对照组为13. 33%(4/30),两组比较差异无统计学意义(P> 0. 05)。结论布地奈德福莫特罗联合孟鲁司特钠治疗支气管哮喘的疗效显著,可改善患者的肺功能,降低炎症因子水平,同时具有良好的用药安全性。
Objective To study the effect of budesonide-formoterol combined with montelukast sodium on the efficacy and level of inflammatory factors in patients with bronchial asthma.Methods The clinical data of 60 patients with bronchial asthma hospitalized in Beijing Daxing District People′s Hospital from Jul.2016 to Jul.2018,were retrospectively analyzed.According to different treatment methods,they were divided into an observation group and a control group,30 cases each.The control group was treated with budesonide-formoterol,and the observation group was combined with montelukast sodium on the basis of the control group′s regimen,one week as a course of treatment,both treated for four courses of treatment.The clinical effects after treatment,the pulmonary function indexes[forced expiratory volume in the first second(FEV 1),peak expiratory flow(PEF),forced vital capacity(FVC)],inflammatory factors[C reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]and the incidence of adverse reactions of the two groups before and after treatment were compared.Results The total effective rate of the observation group was higher than that of the control group[93.33%(28/30)vs 73.33%(22/30)](P<0.05).After treatment,FEV 1,PEF and FVC of both groups increased,the observation group higher than the control group[(82.90±6.71)%vs(78.40±6.82)%,(3.96±0.48)L/s vs(3.59±0.41)L/s,(3.39±0.37)L vs(3.09±0.33)L](P<0.05).After treatment,the levels of serum CRP,IL-6 and TNF-αin both groups were all decreased,the observation group lower than the control group[(164.8±11.6)ng/L vs(187.1±21.8)ng/L,(4.3±1.1)ng/L vs(7.3±1.7)ng/L,(131.5±15.2)μg/L vs(149.8±17.2)μg/L](P<0.05).The total incidence of adverse reactions was 16.67%(5/30)in the observation group and 13.33%(4/30)in the control group,with no significant difference between the two groups(P>0.05).Conclusion Budesonide-formoterol combined with montelukast sodium in the treatment of bronchial asthma has a significant effect,which can improve the lung function of the patients,reduce the level of inflammatory factors,and has a good medication safety.
作者
唐文慧
张伟
李春梅
TANG Wenhui;ZHANG Wei;LI Chunmei(Department of Respiratory and Critical Care Medicine,Beijing Daxing District People′s Hospital,Beijing 102600,China;Department of General Surgery,Beijing Daxing District People′s Hospital,Beijing 102600,China)
出处
《医学综述》
2020年第12期2493-2497,共5页
Medical Recapitulate
关键词
支气管哮喘
布地奈德福莫特罗
孟鲁司特钠
肺功能
炎症因子
Bronchial asthma
Budesonide-formoterol
Montelukast sodium
Lung function
Inflammatory factors
